Scholarlink

Introduction <p>Type 1 diabetes (T1D) results from the destruction of pancreatic β-cells, leading to insulin deficiency. As insulin therapy does not affect disease progression, advancements in immune regulation therapies have emerged, including the reconstitution of the insulin secretory system. Cysteine-rich acidic secretory protein (<i>SPARC</i>) is an extracellular matrix glycoprotein that regulates cell adhesion, facilitating cell migration, and mediating interactions between cells and their extracellular matrix. <i>SPARC</i> is overexpressed during tissue repair and is involved in β-cells survival. However, the potential of <i>SPARC</i>-modified mesenchymal stem cells (MSCs) to improve insulin secretion has not been thoroughly investigated. This study investigated the therapeutic effects of <i>SPARC</i>-MSCs in vivo and in vitro and assessed whether <i>SPARC</i> enhances survival and insulin secretion after β-cells injury.</p> Methods <p>In vivo, we established T1D models in mice and canine using <i>SPARC</i>-MSCs for cell transplantation. In vitro, MIN6 cells were damaged with STZ, and <i>SPARC</i>-MSC supernatant was co-cultured with MIN6 for various assays.</p> Results <p>Our study demonstrated that <i>SPARC</i> enhanced the regenerative capacity and migratory efficiency of MSCs after H<sub>2</sub>O<sub>2</sub> injury and improved their morphology. In STZ-induced canine and mice diabetes models, <i>SPARC</i>-MSCs therapy significantly reduced hyperglycemia, improved oral glucose tolerance test (OGTT), and reversed weight loss in canine. Biochemical analyses showed improved liver function, and histological examination revealed restored islet area was significantly restored. Transcriptome and proteome sequencing indicated significant enrichment in calcium binding and cell migration pathways. Co-culturing <i>SPARC</i>-MSC supernatant with MIN6 cells after STZ injury restored their regenerative ability, enhancing insulin secretion and ATP content under high glucose stimulation. <i>SPARC</i> treatment also significantly increased intracellular Ca<sup>2+</sup> levels in MIN6 cells.</p> Conclusion <p><i>SPARC</i> significantly promotes cell regeneration and stimulates insulin secretion by increasing intracellular ATP and Ca<sup>2+</sup> influx. In diabetic canine and mice models, it alleviated hyperglycemia, improved glucose tolerance, and enhanced pancreatic islet area and insulin secretion.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SPARC-modified mesenchymal stem cells promote recovery of β-cells and insulin secretion by calcium ion homeostasis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月3日

查看全文
  • Jiaqi Gao,
  • Balun Li,
  • Hongkai Tian,
  • Chenchen Li,
  • Nikita Merzlikin,
  • Dongyao Han,
  • Zixi Ling,
  • Zengyu Zhang,
  • Wenlong zhu,
  • Jianqi Dai,
  • Lydmila Gerunova,
  • Changrong Lv,
  • Na Li,
  • Jinlian Hua

摘要

Introduction

Type 1 diabetes (T1D) results from the destruction of pancreatic β-cells, leading to insulin deficiency. As insulin therapy does not affect disease progression, advancements in immune regulation therapies have emerged, including the reconstitution of the insulin secretory system. Cysteine-rich acidic secretory protein (SPARC) is an extracellular matrix glycoprotein that regulates cell adhesion, facilitating cell migration, and mediating interactions between cells and their extracellular matrix. SPARC is overexpressed during tissue repair and is involved in β-cells survival. However, the potential of SPARC-modified mesenchymal stem cells (MSCs) to improve insulin secretion has not been thoroughly investigated. This study investigated the therapeutic effects of SPARC-MSCs in vivo and in vitro and assessed whether SPARC enhances survival and insulin secretion after β-cells injury.

Methods

In vivo, we established T1D models in mice and canine using SPARC-MSCs for cell transplantation. In vitro, MIN6 cells were damaged with STZ, and SPARC-MSC supernatant was co-cultured with MIN6 for various assays.

Results

Our study demonstrated that SPARC enhanced the regenerative capacity and migratory efficiency of MSCs after H2O2 injury and improved their morphology. In STZ-induced canine and mice diabetes models, SPARC-MSCs therapy significantly reduced hyperglycemia, improved oral glucose tolerance test (OGTT), and reversed weight loss in canine. Biochemical analyses showed improved liver function, and histological examination revealed restored islet area was significantly restored. Transcriptome and proteome sequencing indicated significant enrichment in calcium binding and cell migration pathways. Co-culturing SPARC-MSC supernatant with MIN6 cells after STZ injury restored their regenerative ability, enhancing insulin secretion and ATP content under high glucose stimulation. SPARC treatment also significantly increased intracellular Ca2+ levels in MIN6 cells.

Conclusion

SPARC significantly promotes cell regeneration and stimulates insulin secretion by increasing intracellular ATP and Ca2+ influx. In diabetic canine and mice models, it alleviated hyperglycemia, improved glucose tolerance, and enhanced pancreatic islet area and insulin secretion.

Graphical Abstract